Modus Therapeutics Holding AB (DE:99Z)

FRANKFURT:99Z

99Z

Modus Therapeutics Holding AB

RESEARCH TOOLSreports

Want to see DE:99Z full AI Analyst Report?

Modus Therapeutics Holding AB (99Z) Price & Analysis

0 Followers

99Z Stock Chart & Stats

€0.03

>-€0.01(-1.57%)

At close: Jan 08 4:00 PM EST

€0.03

>-€0.01(-1.57%)

Day’s Range― - ―

52-Week Range€0.01 - €0.33

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€4.70M

Enterprise Value€26.92M

Total Cash (Recent Filing)€5.32M

Total Debt (Recent Filing)€5.00M

Price to Earnings (P/E)―

Beta1.89

Next Earnings

May 19, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding121,628,494

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)2.10

Price to Sales (P/S)0.00

P/FCF Ratio-1.05

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.01

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low LeverageZero reported debt across 2023–2025 is a durable credit positive: it reduces fixed financing costs and lowers short-term insolvency risk, giving management flexibility to time financing or pursue partnerships. This structural low leverage supports strategic optionality during clinical development.

Focused Lead Program In SCDA clear, specialized lead program in sickle cell disease builds a focused clinical and regulatory roadmap. Concentration in a rare hematology niche can secure orphan incentives, streamline trial design, and attract targeted partnerships or licensing offers, establishing durable strategic positioning if clinical proof is achieved.

Lean Operating ModelAn extremely small headcount implies a capital-light, outsourced R&D model with low fixed overhead. This lean structure can extend cash runway per financing round, enable rapid scaling through CROs or partners, and preserve flexibility to prioritize programs or conserve capital between milestones.

Bears Say

No RevenueAbsence of revenue over multiple years leaves the company fully dependent on development milestones and external funding. Without product sales, there is no internal cash generation to fund trials, increasing binary clinical risk, lengthening the path to self-sufficiency, and magnifying financing vulnerability.

Persistent Cash BurnConsistent negative operating and free cash flow, worsening to about -SEK 18.1m in 2025, signals structural cash consumption tied to ongoing R&D. This requires recurrent capital raises or partnerships, increases dilution risk, and can force trade-offs on program timelines or scope absent durable financing sources.

Financing Dependence / Equity VolatilityA volatile and small equity base reflects repeated recapitalization and reliance on external funding. Structural dependence on equity raises dilution risk, can constrain strategic choices, and creates execution uncertainty if markets or partner interest dries up, undermining long-term shareholder value.

99Z FAQ

What was Modus Therapeutics Holding AB’s price range in the past 12 months?

Modus Therapeutics Holding AB lowest stock price was €0.01 and its highest was €0.33 in the past 12 months.

What is Modus Therapeutics Holding AB’s market cap?

Modus Therapeutics Holding AB’s market cap is €4.70M.

When is Modus Therapeutics Holding AB’s upcoming earnings report date?

Modus Therapeutics Holding AB’s upcoming earnings report date is May 19, 2026 which is in 18 days.

How were Modus Therapeutics Holding AB’s earnings last quarter?

Modus Therapeutics Holding AB released its earnings results on Feb 25, 2026. The company reported -€0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.004.

Is Modus Therapeutics Holding AB overvalued?

According to Wall Street analysts Modus Therapeutics Holding AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Modus Therapeutics Holding AB pay dividends?

Modus Therapeutics Holding AB does not currently pay dividends.

What is Modus Therapeutics Holding AB’s EPS estimate?

Modus Therapeutics Holding AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Modus Therapeutics Holding AB have?

Modus Therapeutics Holding AB has 121,628,494 shares outstanding.

What happened to Modus Therapeutics Holding AB’s price movement after its last earnings report?

Modus Therapeutics Holding AB reported an EPS of -€0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.882%.

Which hedge fund is a major shareholder of Modus Therapeutics Holding AB?

Currently, no hedge funds are holding shares in DE:99Z

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Modus Therapeutics Holding AB

Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. Its lead product is Sevuparin, a polysaccharide to treat patients with sepsis and septic shock, which is under Phase Ib clinical study. The company was founded in 2011 and is headquartered in Stockholm, Sweden.